The Efficacy of Topical Sesame Oil Versus Topical Triamcinolone on Oral Lichen Planus and Salivary Level of Oxidative Stress Biomarker [MDA]

The Efficacy of Topical Sesame Oil in Orabase Versus Topical Triamcinolone in Orabase on Oral Lichen Planus and Salivary Level of Oxidative Stress Biomarker, Malondialdehyde [MDA] : Randomized Clinical Trial (RCT)

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03738176

Acronym

(MDA)

Enrollment

Registered

2018-11-13

Start date

2019-12-16

Completion date

2020-12-30

Last updated

2019-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Lichen Planus

Keywords

Oral lichen planus, sesame oil, corticosteroid, MDA

Brief summary

use seseme oil and corticosteroid topically for two groups

Detailed description

* The enrolled patients will be divided randomly into two groups. * Test group will receive topical sesame oil (3 times /day after eating) for a month. * Control group will receive topical corticosteroid (3 times /day after eating) for a month. * Assessment of the appearance score and severity of pain as well as the clinical parameter outcome will be done at baseline and at the end of two and four weeks and will be recorded in the patients' questionnaires & by clinical sign score . MDA will be measured at the baseline & at the end of four weeks after treatment.

Interventions

DRUGSesame Oil

Sesame oil(80 gm NaCMC-20 gmSesame oil)

DRUGtriamcinolone in orabase

triamcinolone 140 gm-Na CMC 50 gm

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Intervention model description

sesame oil in orabase(80 gm CMC -20 gm sesame oil)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients who will be clinically diagnosed as having atrophic &/or erosive oral lichen planus. * Patients with no history of taking topical corticosteroids for the last 2 months and systemic corticosteroid for the last 6 months * Patients who agree to take medication and follow up .

Exclusion criteria

* Pregnant and lactating ladies. * Patients with history of topical steroids during last 2 months & systemic steroids during last 6 months. * Patients with recent dental filling associated with the lesion or associated with recent drug administration. * Patient with history of diabetes or hypertension or those with positive HCV ab or HBs Ag.

Design outcomes

Primary

Measure	Time frame	Description
pain intensit measure	4 weeks	measured by visual analogue scale where0 no pain and 10 sever pain
reduction of clinical signs measure	4 weeks	Thongprasom Score 5 = white striae with erosive area = 1 cm2 Score 4 = white striae with erosive area \< 1 cm2 Score 3 = white striae with erosive area \> 1 cm2 Score 2 = white striae with atrophic area \< 1 cm2 Score 1 = mild white striae only Score 0 = no lesion normal

Secondary

Measure	Time frame	Description
Salivary level of oxidative stress biomarker (MDA)	4 weeks	measured by reaction with thiobarbituric acid (TBA)

Contacts

Primary ContactMona Taha Mohammed Ahamed, Master

mona.taha@dentistry.cu.edu.eg01123294474

Backup ContactAmal ALI Ali, LEcturer

amal.ali@dentistry.cu.edu.eg01156520918

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026